Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Core Insights - Adial Pharmaceuticals, Inc. has filed an update to its provisional patent application for AD04, a genetically targeted therapeutic agent for Alcohol Use Disorder (AUD), which is expected to protect its core assets until at least 2045 [1][2] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders, with its lead investigational drug AD04 targeting AUD in heavy drinking patients [3] - AD04 has shown promising results in the ONWARD™ pivotal Phase 3 clinical trial, demonstrating effectiveness in reducing drinking among heavy drinkers without significant safety or tolerability concerns [3] Patent and Regulatory Strategy - The new patent application for AD04 is a result of extensive data examination and aims to bolster Adial's intellectual property portfolio, with an upcoming End-of-Phase 2 Meeting with the FDA scheduled for July 29, 2025 [2] - The patent's approval is crucial for extending the protection of Adial's core assets and supporting the advancement of the AD04 program [2]